Press Releases

<<  Back

  View printer-friendly version

Aimmune Therapeutics to Participate in Three Investor Conferences in September

BRISBANE, Calif.--(BUSINESS WIRE)--Sep. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will be presenting at three upcoming investor conferences in September.

Event: BioCentury NewsMakers in the Biotech Industry
Date:Friday, September 8, 2017
Time:11:00 a.m. Eastern Time
Location: New York
Presenter: CFO Eric Bjerkholt

Event: Bank of America Merrill Lynch Global Healthcare Conference
Date:Friday, September 15, 2017
Time:10:40 a.m. British Summer Time
Location: London
Presenter: CEO Stephen Dilly, M.B.B.S., Ph.D.

Event: Cantor Fitzgerald Global Healthcare Conference
Date:Tuesday, September 26, 2017
Time:9:10 a.m. Eastern Time
Location:New York
Presenter: CFO Eric Bjerkholt

Live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Replays of the webcasts will be available for at least 30 days following each webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

Source: Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc.
Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com
or
Media
Stephanie Yao, 650-351-6479
syao@aimmune.com